换一批
换一批SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy.
作者：
Chiara,De-Colle [1]
;
Apostolos,Menegakis [2]
;
David,Mönnich [3]
;
Stefan,Welz [2]
;
Simon,Boeke [2]
;
Bence,Sipos [4]
;
Falko,Fend [4]
;
Paul-Stefan,Mauz [5]
;
Inge,Tinhofer [6]
;
Volker,Budach [6]
;
Jehad,Abu Jawad [7]
;
Martin,Stuschke [7]
;
Panagiotis,Balermpas [8]
;
Claus,Rödel [8]
;
Anca-Ligia,Grosu [9]
;
Amir,Abdollahi [10]
;
Jürgen,Debus [11]
;
Claus,Belka [12]
;
Ute,Ganswindt [12]
;
Steffi,Pigorsch [13]
;
Stephanie E,Combs [13]
;
Fabian,Lohaus [14]
;
Annett,Linge [15]
;
Mechthild,Krause [16]
;
Michael,Baumann [17]
;
Daniel,Zips [3]
;
DKTK-ROG
作者单位：
Radiation Oncology, Medical Faculty and University Hospital, Eberhard Karls University Tübingen, Germany. Electronic address: chiara.de-colle@med.uni-tuebingen.de.
[1]
Radiation Oncology, Medical Faculty and University Hospital, Eberhard Karls University Tübingen, Germany.
[2]
Radiation Oncology, Medical Faculty and University Hospital, Eberhard Karls University Tübingen, Germany; German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK) partner site Tübingen, Germany.
[3]
Department of Pathology, Medical Faculty and University Hospital, Eberhard Karls University Tübingen, Germany.
[4]
Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty and University Hospital, Eberhard Karls University Tübingen, Germany.
[5]
German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK) partner site Berlin, Germany; Department of Radiooncology and Radiotherapy, Charité University Hospital, Berlin, Germany.
[6]
German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK) partner site Essen, Germany; Department of Radiotherapy, Medical Faculty, University of Duisburg-Essen, Germany.
[7]
German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK) partner site Frankfurt, Germany; Department of Radiotherapy and Oncology, Goethe-University Frankfurt, Germany.
[8]
German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK) partner site Freiburg, Germany; Department of Radiation Oncology, University of Freiburg, Germany.
[9]
German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK) partner site Heidelberg, Germany; Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany; Heidelberg Ion Therapy Center (HIT), Department of Radiation Oncology, University of Heidelberg Medical School, Germany; National Center for Tumor Diseases (NCT), University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany; Translational Radiation Oncology, University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany.
[10]
German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK) partner site Heidelberg, Germany; Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany; Heidelberg Ion Therapy Center (HIT), Department of Radiation Oncology, University of Heidelberg Medical School, Germany; National Center for Tumor Diseases (NCT), University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany; Clinical Cooperation Unit Radiation Oncology, University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany.
[11]
German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK) partner site Munich, Germany; Department of Radiotherapy and Radiation Oncology, Ludwig-Maximilians-Universität, Munich, Germany.
[12]
German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK) partner site Munich, Germany; Department of Radiation Oncology, Technische Universität München, Germany.; Institute for Innovative radiation therapy in Helmholtz-Zentrum München, Germany.
[13]
German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK) partner site Dresden, Germany; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Germany; Helmholtz-Zentrum Dresden - Rossendorf, Institute of Radiooncology - OncoRay, Germany.
[14]
German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK) partner site Dresden, Germany; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Germany; National Center for Tumor Diseases (NCT), partner site Dresden, Germany.
[15]
German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK) partner site Dresden, Germany; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Germany; National Center for Tumor Diseases (NCT), partner site Dresden, Germany; Helmholtz-Zentrum Dresden - Rossendorf, Institute of Radiooncology - OncoRay, Germany.
[16]
German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK) partner site Dresden, Germany; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Germany; National Center for Tumor Diseases (NCT), partner site Dresden, Germany; Helmholtz-Zentrum Dresden - Rossendorf, Institute of Radiooncology - OncoRay, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany.
[17]
主题词
老年人(Aged);癌, 鳞状细胞(Carcinoma, Squamous Cell);趋化因子CXCL12(Chemokine CXCL12);女(雌)性(Female);头颈部肿瘤(Head and Neck Neoplasms);人类(Humans);男(雄)性(Male);中年人(Middle Aged);肿瘤复发, 局部(Neoplasm Recurrence, Local);肿瘤分期(Neoplasm Staging);预后(Prognosis);前瞻性研究(Prospective Studies);受体, CXCR4(Receptors, CXCR4);回顾性研究(Retrospective Studies);存活率(Survival Rate)
DOI
10.1016/j.radonc.2017.10.008
PMID
29061496
发布时间
2019-02-21
- 浏览11
Radiotherapy and oncology
Radiotherapy and oncology
125-131页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
